{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T17:06:55Z","timestamp":1779815215910,"version":"3.53.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Recordati Rare Diseases Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Idiopathic multicentric Castleman disease (iMCD) is a rare condition with a wide range of signs and symptoms that often overlap with other conditions that cause lymphadenopathy. The diagnosis of iMCD remains challenging, even among experts. Our aim is to highlight the heterogeneity of histopathologic features and presentations of iMCD and to provide tools to help diagnose and raise awareness of this rare condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We review the most relevant clinicopathologic aspects of iMCD and present our process to accurately diagnose this condition using a case-based approach. We describe how to incorporate the iMCD diagnostic criteria, including grading of histomorphology, laboratory, and clinical findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here, we describe our system to grade histopathologic features in iMCD. Together with radiologic findings and laboratory and clinical information, this system helps clinicians accurately identify iMCD and its subtypes, leading to more appropriate and timely diagnosis and treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The diagnosis of iMCD can be challenging and requires a multidisciplinary team of hematologists, pathologists\/hematopathologists, and other specialists. There is a pressing and unmet clinical need for a harmonized system to grade the histopathologic features of iMCD. This condition should be included in the differential diagnosis when other causes of a lymphoproliferative disorder (eg, infections, autoimmune\/inflammatory disorders, malignancy) have been ruled out.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqaf134","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:02:12Z","timestamp":1762866132000},"source":"Crossref","is-referenced-by-count":0,"title":["Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist\u2019s perspective"],"prefix":"10.1093","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3414-8375","authenticated-orcid":false,"given":"Daisy V","family":"Alapat","sequence":"first","affiliation":[{"name":"University of Arkansas for Medical Sciences Department of Pathology, , Little Rock, AR 72205,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5301-434X","authenticated-orcid":false,"given":"Payam","family":"Etebari","sequence":"additional","affiliation":[{"name":"Recordati Rare Diseases , Bridgewater, NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-1282","authenticated-orcid":false,"given":"Frits","family":"Van Rhee","sequence":"additional","affiliation":[{"name":"Myeloma Center, University of Arkansas for Medical Sciences , Little Rock, AR,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"2026052612515222500_aqaf134-B1","first-page":"1001","article-title":"Case records of the Massachusetts General Hospital: case No. 40231","volume":"250","author":"Castleman","year":"1954","journal-title":"N Engl J Med"},{"key":"2026052612515222500_aqaf134-B2","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/1097-0142(195607\/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4","article-title":"Localized mediastinal lymphnode hyperplasia resembling thymoma","volume":"9","author":"Castleman","year":"1956","journal-title":"Cancer"},{"key":"2026052612515222500_aqaf134-B3","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO;2-#","article-title":"Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations","volume":"29","author":"Keller","year":"1972","journal-title":"Cancer"},{"key":"2026052612515222500_aqaf134-B4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.23291","article-title":"The clinical spectrum of Castleman\u2019s disease","volume":"87","author":"Dispenzieri","year":"2012","journal-title":"Am J Hematol"},{"key":"2026052612515222500_aqaf134-B5","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1182\/bloodadvances.2020003334","article-title":"International evidence-\u00adbased consensus diagnostic and treatment guidelines for unicentric Castleman disease","volume":"4","author":"van Rhee","year":"2020","journal-title":"Blood Adv"},{"key":"2026052612515222500_aqaf134-B6","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"key":"2026052612515222500_aqaf134-B7","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1056\/NEJM199403033300904","article-title":"Brief report: alleviation of systemic manifestations of Castleman\u2019s disease by monoclonal anti-interleukin-6 antibody","volume":"330","author":"Beck","year":"1994","journal-title":"N Engl J Med"},{"key":"2026052612515222500_aqaf134-B8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/bloodadvances.2021004441","article-title":"Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy","volume":"6","author":"Mukherjee","year":"2022","journal-title":"Blood Adv"},{"key":"2026052612515222500_aqaf134-B9","first-page":"320","article-title":"Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly","volume":"51","author":"Takai","year":"2010","journal-title":"Rinsho Ketsueki"},{"key":"2026052612515222500_aqaf134-B10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3960\/jslrt.53.57","article-title":"Castleman-Kojima Disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012)","volume":"53","author":"Kawabata","year":"2013","journal-title":"J Clin Exp Hematop"},{"key":"2026052612515222500_aqaf134-B11","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"key":"2026052612515222500_aqaf134-B12","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood"},{"key":"2026052612515222500_aqaf134-B13","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/ajh.25992","article-title":"Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease","volume":"95","author":"Fajgenbaum","year":"2020","journal-title":"Am J Hematol"},{"key":"2026052612515222500_aqaf134-B14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41572-021-00317-7","article-title":"Castleman disease","volume":"7","author":"Carbone","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026052612515222500_aqaf134-B15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/his.12213","article-title":"Increased CD5-positive polyclonal B cells in Castleman disease: a diagnostic pitfall","volume":"63","author":"Liu","year":"2013","journal-title":"Histopathology"},{"key":"2026052612515222500_aqaf134-B16","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/00000478-199809000-00002","article-title":"Reticulum cell neoplasms of lymph nodes: a clinicopathologic study of 11 cases with recognition of a new subtype derived from fibroblastic reticular cells","volume":"22","author":"Andriko","year":"1998","journal-title":"Am\u00a0J Surg Pathol"},{"key":"2026052612515222500_aqaf134-B17","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/00000478-200205000-00013","article-title":"Hyaline vascular Castleman\u2019s disease with HMGIC rearrangement in follicular dendritic cells: molecular evidence of mesenchymal tumorigenesis","volume":"26","author":"Cokelaere","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"2026052612515222500_aqaf134-B18","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/modpathol.2013.202","article-title":"Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease","volume":"27","author":"Chang","year":"2014","journal-title":"Mod Pathol"},{"key":"2026052612515222500_aqaf134-B19","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/diagnostics12020406","article-title":"A cytological review of follicular dendritic cell-derived tumors with emphasis on follicular dendritic cell sarcoma and unicentric Castleman disease","volume":"12","author":"Jim\u00e9nez-Heffernan","year":"2022","journal-title":"Diagnostics"},{"key":"2026052612515222500_aqaf134-B20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.hoc.2017.09.004","article-title":"Pathology of Castleman disease","volume":"32","author":"Wu","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026052612515222500_aqaf134-B21","author":"WHO Classification of Tumours Editorial Board","year":"2017"},{"key":"2026052612515222500_aqaf134-B22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3960\/jslrt.21038","article-title":"Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?","volume":"62","author":"Nishimura","year":"2022","journal-title":"J Clin Exp Hematop"},{"key":"2026052612515222500_aqaf134-B23","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1440-1827.2000.01052.x","article-title":"Reactive follicular hyperplasia in the lymph node lesions from systemic lupus erythematosus patients: a clinicopathological and immunohistological study of 21 cases","volume":"50","author":"Kojima","year":"2000","journal-title":"Pathol Int"},{"key":"2026052612515222500_aqaf134-B24","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopha.2006.09.004","article-title":"Benign, atypical and malignant lymphoproliferative disorders in rheumatoid arthritis patients","volume":"60","author":"Kojima","year":"2006","journal-title":"Biomed Pharmacother"},{"key":"2026052612515222500_aqaf134-B25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.prp.2007.03.002","article-title":"Histological diversity of reactive and atypical proliferative lymph node lesions in systemic lupus erythematosus patients","volume":"203","author":"Kojima","year":"2007","journal-title":"Pathol Res Pract"},{"key":"2026052612515222500_aqaf134-B26","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/S2352-3026(16)00006-5","article-title":"Idiopathic multicentric Castleman\u2019s disease: a systematic literature review","volume":"3","author":"Liu","year":"2016","journal-title":"Lancet Haematol"},{"key":"2026052612515222500_aqaf134-B27","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/rheumatology\/keab634","article-title":"Immunoglobulin G4-related disease and idiopathic multicentric Castleman\u2019s disease: confusable immune-mediated disorders","volume":"61","author":"Sasaki","year":"2022","journal-title":"Rheumatology (Oxford))"},{"key":"2026052612515222500_aqaf134-B28","doi-asserted-by":"crossref","first-page":"e1263","DOI":"10.1002\/onco.13801","article-title":"Histiocytic and dendritic cell sarcomas of hematopoietic origin share targetable genomic alterations distinct from follicular dendritic cell sarcoma","volume":"26","author":"Massoth","year":"2021","journal-title":"Oncologist"},{"key":"2026052612515222500_aqaf134-B29","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ajh.26240","article-title":"POEMS syndrome: 2021 updated on diagnosis, risk-\u00adstratification, and management","volume":"96","author":"Dispenzieri","year":"2021","journal-title":"Am J Hematol"},{"key":"2026052612515222500_aqaf134-B30","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/ajh.26292","article-title":"Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease","volume":"96","author":"Nishimura","year":"2021","journal-title":"Am J Hematol"},{"key":"2026052612515222500_aqaf134-B31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"}],"container-title":["Am J Clin Path"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/3\/aqaf134\/67211095\/aqaf134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/3\/aqaf134\/67211095\/aqaf134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:52:01Z","timestamp":1779814321000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/doi\/10.1093\/ajcp\/aqaf134\/8504308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaf134","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]},"article-number":"aqaf134"}}